Last reviewed · How we verify
Low titre
At a glance
| Generic name | Low titre |
|---|---|
| Sponsor | Hvivo |
| Modality | Biologic |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Massive Transfusion in Children-2: A Trial Examining Life Threatening Hemorrhage in Children (PHASE3)
- Type O Whole Blood and Assessment of Age During Prehospital Resuscitation Trial (PHASE3)
- Dose, Safety and Pathogenicity of SARS-CoV-2 (COVID-19) Omicron Virus (BA.5) (EARLY_PHASE1)
- A Gene Transfer Therapy to Evaluate the Safety and Efficacy of Delandistrogene Moxeparvovec (SRP-9001) Following Therapeutic Plasma Exchange (Plasmapheresis) in Participants With Duchenne Muscular Dystrophy (DMD) and Pre-existing Antibodies to AAVrh74 (PHASE1)
- Trauma Resuscitation With Low-Titer Group O Whole Blood or Products (PHASE3)
- Optimization Strategies for Blood Transfusion Protocols in the Emergency Treatment of Hemorrhagic Shock (PHASE3)
- Biweekly Actinomycin-D Treatment or Multi-day Methotrexate Protocol in Low-risk Gestational Trophoblastic Neoplasia (NA)
- Low-Titer O Positive Whole Blood Versus Component Therapy for Emergent Transfusion in Trauma Patients (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Low titre CI brief — competitive landscape report
- Low titre updates RSS · CI watch RSS
- Hvivo portfolio CI